Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: mecasermin recombinant

« Back to Dashboard
Mecasermin recombinant is the generic ingredient in one branded drug marketed by Ipsen Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for Generic Name: mecasermin recombinant

Drug Master File Entries: 0
Suppliers: see list1

Clinical Trials for: mecasermin recombinant

Treatment of Rett Syndrome With Recombinant Human IGF-1
Status: Recruiting Condition: Rett Syndrome

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-Like Growth Factor-1 Deficiency; Growth Disorders

Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Status: Completed Condition: Disorder of Bone Density and Structure, Unspecified

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
Status: Completed Condition: Growth Disorders; Insulin-Like Growth Factor-1 Deficiency

Effects of IGF-I in HIV Metabolic Disease
Status: Terminated Condition: HIV Lipodystrophy

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
Status: Terminated Condition: Noonan Syndrome

Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
Status: Terminated Condition: Growth Disorders

IGF-1 Therapy in Patients With Cystic Fibrosis
Status: Terminated Condition: Cystic Fibrosis

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
Status: Completed Condition: Insulin-like Growth Factor-1 Deficiency

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
Status: Terminated Condition: Growth Hormone Deficiency

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Inc
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005RXYes5,681,814<disabled>Y<disabled>
Ipsen Inc
mecasermin recombinant
INJECTABLE;SUBCUTANEOUS021839-001Aug 30, 2005RXYes5,824,642<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn